modifications to the chromatographic procedure. This modified procedure allowed quantification of 17-20 individual bile acids to as little as about 150 nmol/L. The percent analytical recovery for added free and conjugated lithocholic acids averaged 80.8% and for the other bile acids averaged 97.4%. The fluorometric signal for this assay varied linearly with bile acid concentration from the lower limit of quantification to at least 30000 nmol/L. The diminished analytical time and the increased species versatility permitted by our modifications make this assay clinically appealing. Incubate sample, antibody, and label with the bead at room temperature for 2 h with gentle horizontal shaking or overnight at 4 #{176}C. Wash the bead, then add the detection solution (a catalyst in alkaline peroxidase solution) and measure the luminometric signal (we used a Model LB 952 automated luminometer from Berthold, Nashua, NH).
In gynecological practice, serial determinations of 17/3-estradiol (17/3-E2), progesterone, and lutropin (LH) in plasma during the menstrual cycle are used to assess corpus luteuin function (1) . Ovarian function can also be evaluated by measuring LH and the key metabolite of progesterone, pregnanediol-3a-glucuronide, and of 17/3-E2, estrone-3-glucuronide, in urine (2). Urinary determinations permit monitoring of ovarian function without the problems of pulsatile hormone release that affect serum assays or invasive sampling. In our laboratory, we have developed iminunochemiluminescence assays (ICLAs) for the above two steroid metabolites and demonstrated their clinical usefulness (3). These assays require untimed, early morning urine samples, as described previously (4). Now, to complete the set of methods for profiling ovarian function, we have developed a competitive ICLA to quantilr LII in urine samples, based on use of an isoluminol tracer.
This method involves a single-step incubation in which a bead coated with a goat anti-mouse Ig works as the separation system. The other reagents are 200 uL of sample (standard or undiluted urine sample), 50 pL of murine monoclonal anti-LH antibody, and 50 zL of LII conjugated with 6-W-(4aminobutyl)-N-ethylamino]-2,3-dihydrophthalazine-1,4-dione tracer. We calibrated the standard against the reference preparation from WHO (1st IRP 68/40).
Incubate sample, antibody, and label with the bead at room temperature for 2 h with gentle horizontal shaking or overnight at 4 #{176}C. Wash the bead, then add the detection solution (a catalyst in alkaline peroxidase solution) and measure the luminometric signal (we used a Model LB 952 automated luminometer from Berthold, Nashua, NH).
We evaluated the imprecision profile of the assay within the concentration range of 5 to 100 mt.units/L. Within this working range, the CV never exceeded 10%. The intraassay CV, calculated for 10 sample replicates, was 5%. Accuracy was evaluated by analytical recovery and dilution tests. Analytical recovery within the same concentra- To prove the method clinically reliable, we monitored ovarian function of 10 normal women (ages 21-42 years). The urine samples, collected daily during the menstrual cycle, were analyzed for LH, pregnanediol-3a-glucuronide, and estrone-3-glucuronide. As Figure 1 shows, the peak concentration of urinary LH is consistent with the trend for the other two metabolites and thus is coherent with the physiological status.
These data demonstrate that this ICLA of urinary LII is methodologically consistent and reliable for use in clinical practice. We measured catalytic concentrations of ADA in serum from a control group of women (n = 22; ages 20-45 years) and from pregnant women (n = 84; ages 20-39 years) as described elsewhere (4). Fasting blood samples were obtained by venipuncture.
At the time of blood collection, none of the women were taking any drugs. All variables were controlled according to IFCC recommendations (5) . In all cases, the enzyme activities in serum exhibited a gaussian distribution.
Concentrations of serum ADA differed significantly (P = 0.000 14) between the groups but not between each trimester of pregnancy (Table 1) . We conclude that ADA concentrations in serum might be a marker of depressed cell-mediated immunity in pregnancy.
